Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has been assigned an average recommendation of “Hold” from the thirty research firms that are currently covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, fifteen have issued a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. The average 12 month price target among analysts that have covered the stock in the last year is $469.95.
A number of equities analysts recently commented on REGN shares. Zacks Investment Research cut Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, October 10th. Jefferies Group reaffirmed a “hold” rating and issued a $500.00 target price (up from $471.00) on shares of Regeneron Pharmaceuticals in a report on Friday, October 6th. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $540.00 target price on shares of Regeneron Pharmaceuticals in a report on Friday, September 29th. J P Morgan Chase & Co reaffirmed a “hold” rating on shares of Regeneron Pharmaceuticals in a report on Tuesday, October 31st. Finally, Evercore ISI decreased their target price on Regeneron Pharmaceuticals from $605.00 to $445.00 and set an “outperform” rating on the stock in a report on Thursday, November 16th.
Regeneron Pharmaceuticals (REGN) traded up $3.23 during midday trading on Thursday, hitting $361.86. The stock had a trading volume of 1,292,671 shares, compared to its average volume of 908,013. Regeneron Pharmaceuticals has a 12-month low of $340.09 and a 12-month high of $543.55. The company has a market cap of $38,540.00, a PE ratio of 31.69, a price-to-earnings-growth ratio of 1.44 and a beta of 1.56. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.63 and a quick ratio of 3.07.
In other news, CFO Robert E. Landry sold 189 shares of the firm’s stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $501.06, for a total transaction of $94,700.34. Following the completion of the transaction, the chief financial officer now owns 10,099 shares in the company, valued at $5,060,204.94. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Robert E. Landry sold 663 shares of the firm’s stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $498.60, for a total value of $330,571.80. Following the transaction, the senior vice president now owns 10,099 shares of the company’s stock, valued at approximately $5,035,361.40. The disclosure for this sale can be found here. Over the last three months, insiders have sold 4,352 shares of company stock worth $2,037,772. Insiders own 10.80% of the company’s stock.
Institutional investors have recently modified their holdings of the company. Oppenheimer & Co. Inc. grew its position in shares of Regeneron Pharmaceuticals by 20.6% during the second quarter. Oppenheimer & Co. Inc. now owns 7,007 shares of the biopharmaceutical company’s stock valued at $3,441,000 after purchasing an additional 1,199 shares in the last quarter. Dupont Capital Management Corp purchased a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at about $220,000. Shell Asset Management Co. grew its position in shares of Regeneron Pharmaceuticals by 24.1% during the third quarter. Shell Asset Management Co. now owns 15,435 shares of the biopharmaceutical company’s stock valued at $5,565,000 after purchasing an additional 2,999 shares in the last quarter. Blair William & Co. IL grew its position in shares of Regeneron Pharmaceuticals by 4.8% during the second quarter. Blair William & Co. IL now owns 1,713 shares of the biopharmaceutical company’s stock valued at $841,000 after purchasing an additional 79 shares in the last quarter. Finally, Principal Financial Group Inc. grew its position in shares of Regeneron Pharmaceuticals by 2.4% during the second quarter. Principal Financial Group Inc. now owns 115,201 shares of the biopharmaceutical company’s stock valued at $56,580,000 after purchasing an additional 2,646 shares in the last quarter. Hedge funds and other institutional investors own 69.47% of the company’s stock.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.